


JC09 Rec'd PCT/PTO 14 DEC 2001

FORM PTO-1390 (REV 10-94)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTORNEY'S DOCKET NUMBER 13390.2USWO
TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371			U.S. APPLICATION NO. (If known, see 37 C.F.R. 1.5) UNKNOWN 10/018719
INTERNATIONAL APPLICATION NO. PCT/EP00/05517	INTERNATIONAL FILING DATE JUNE 15, 2000	PRIORITY DATE CLAIMED JUNE 17, 1999	
TITLE OF INVENTION USE OF GROWTH HORMONE (HGH) FOR THE TREATMENT OF SEXUAL FUNCTIONAL DISTURBANCES			
APPLICANT(S) FOR DO/EO/US BECKER, Armin Johannes; STIEF, Christian George; UCKERT, Stefan; JONAS, Udo			
Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:			
<ol style="list-style-type: none"> <li>1. <input checked="" type="checkbox"/> This is a <b>FIRST</b> submission of items concerning a filing under 35 U.S.C. 371.</li> <li>2. <input type="checkbox"/> This is a <b>SECOND</b> or <b>SUBSEQUENT</b> submission of items concerning a filing under 35 U.S.C. 371.</li> <li>3. <input checked="" type="checkbox"/> This express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(I).</li> <li><input checked="" type="checkbox"/> A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date.</li> <li><input checked="" type="checkbox"/> A copy of the International Application as filed (35 U.S.C. 371(c)(2))               <ol style="list-style-type: none"> <li>a. <input checked="" type="checkbox"/> is transmitted herewith (required only if not transmitted by the International Bureau).</li> <li>b. <input checked="" type="checkbox"/> has been transmitted by the International Bureau.</li> <li>c. <input type="checkbox"/> is not required, as the application was filed in the United States Receiving Office (RO/US)</li> </ol> </li> <li><input type="checkbox"/> A translation of the International Application into English (35 U.S.C. 371(c)(2)).</li> <li><input checked="" type="checkbox"/> Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3))               <ol style="list-style-type: none"> <li>a. <input type="checkbox"/> are transmitted herewith (required only if not transmitted by the International Bureau).</li> <li>b. <input type="checkbox"/> have been transmitted by the International Bureau.</li> <li>c. <input type="checkbox"/> have not been made; however, the time limit for making such amendments has NOT expired.</li> <li>d. <input checked="" type="checkbox"/> have not been made and will not be made.</li> </ol> </li> <li><input type="checkbox"/> A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).</li> <li><input checked="" type="checkbox"/> An unsigned oath or declaration of the inventor(s) (35 U.S.C. 371 (c)(4)).</li> <li>10. <input type="checkbox"/> A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).</li> </ol>			
Items 11. to 16. below concern document(s) or information included:			
11. <input type="checkbox"/> An Information Disclosure Statement under 37 CFR 1.97 and 1.98.			
12. <input type="checkbox"/> An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.			
13. <input checked="" type="checkbox"/> A FIRST preliminary amendment. <input type="checkbox"/> A SECOND or SUBSEQUENT preliminary amendment.			
14. <input type="checkbox"/> A substitute specification.			
15. <input type="checkbox"/> A change of power of attorney and/or address letter.			
16. <input checked="" type="checkbox"/> Other items or information: PCT/EP00/05517, PCT/ISA/210, PCT/IB/308; PCT/IPEA/409			

531 Rec'd PCT/PT 14 DEC 2001

U.S. APPLICATION NO (if known, see 37 CFR 1.5) UNKNOWN <b>10/018719</b>		INTERNATIONAL APPLICATION NO PCT/EP00/05517		ATTORNEY'S DOCKET NUMBER 13390.2USWO	
17. <input checked="" type="checkbox"/> The following fees are submitted:				CALCULATIONS PTO USE ONLY	
<b>BASIC NATIONAL FEE (37 CFR 1.492(a) (1)-(5)):</b> Search Report has been prepared by the EPO or JPO.....\$890.00  International preliminary examination fee paid to USPTO (37 CFR 1.492(a)(1)).....\$710.00  No international preliminary examination fee paid to USPTO (37 CFR 1.482) but international search fee paid to USPTO (37 CFR 1.445(a)(2)).....\$740.00  Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(3)) paid to USPTO ..... \$1040.00  International preliminary examination fee paid to USPTO (37 CFR 1.482) and all claims satisfied provisions of PCT Article 33(2)-(4) .....\$100.00					
<b>ENTER APPROPRIATE BASIC FEE AMOUNT =</b>				\$890.00	
Surcharge of \$130.00 for furnishing the oath or declaration later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(e)).				\$0	
CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE		
Total claims	11 -20 = 0		X \$18.00	\$0	
Independent claims	2 -3 = 0		X \$84.00	\$0	
MULTIPLE DEPENDENT CLAIM(S) (if applicable)			+ \$260.00	\$0	
<b>TOTAL OF ABOVE CALCULATIONS =</b>				\$890.00	
Reduction by 1/2 for filing by small entity, if applicable. Small entity status is claimed pursuant to 37 CFR 1.27				\$0	
<b>SUBTOTAL =</b>				\$890.00	
Processing fee of \$130.00 for furnishing the English translation later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(f)).				+ \$0	
<b>TOTAL NATIONAL FEE =</b>				\$890.00	
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property				+ \$0	
<b>TOTAL FEES ENCLOSED =</b>				\$890.00	
				Amount to be: refunded	\$0
				charged	\$0
a. <input checked="" type="checkbox"/> Check(s) in the amount of \$890.00 to cover the above fees is enclosed.					
b. <input type="checkbox"/> Please charge my Deposit Account No. _____ in the amount of \$ _____ to cover the above fees. A duplicate copy of this sheet is enclosed.					
c. <input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. <u>13-2725</u> .					
<b>NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.</b>					
SEND ALL CORRESPONDENCE TO Ronald A. Daignault MERCHANT & GOULD P.O. Box 2903 Minneapolis, MN 55402-0903					
SIGNATURE:  NAME: Ronald A. Daignault REGISTRATION NUMBER: 25,968					

JC89 Rec'd PCT/PTO 14 DEC 2001

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

10/018719

Applicant: BECKER, et al.  
 Docket: 13390.2USWO  
 Title: USE OF GROWTH HORMONE (HGH) FOR THE TREATMENT OF SEXUAL  
 FUNCTIONAL DISTURBANCES

## CERTIFICATE UNDER 37 CFR 1.10

'Express Mail' mailing label number EL669945412US

Date of Deposit December 14, 2001

I hereby certify that this paper or fee is being deposited with the United States Postal Service 'Express Mail Post Office  
 To Addressee' service under 37 CFR 1.10 and is addressed to the Commissioner for Patents, Washington, D.C. 20231

By   
 Name Chris Stordahl

## BOX PATENT APPLICATION

Commissioner for Patents  
 Washington, D.C. 20231

Sir:

We are transmitting herewith the attached:


- ☒ Transmittal sheet, in duplicate, containing Certificate under 37 CFR 1.10.
- ☒ National Stage PCT Patent Application: Spec. 8 pgs; 11 claims; Abstract 1 pgs.  
The fee has been calculated as shown below in the 'Claims as Filed' table.
- ☒ 2 sheets of formal drawings
- ☒ An unsigned Combined Declaration and Power of Attorney
- ☒ A check in the amount of \$890.00 to cover the Filing Fee
- ☒ Other: PCT/EP00/05517, Preliminary Amendment, PCT/ISA/210; PCT/IB/308; PCT/IPEA/409
- ☒ Return postcard

## CLAIMS AS FILED

Number of Claims Filed		In Excess of:		Number Extra		Rate		Fee
Basic Filing Fee								\$890.00
Total Claims								
11	-	20	=	0	x	18.00	=	\$0.00
Independent Claims								
2	-	3	=	0	x	84.00	=	\$0.00
MULTIPLE DEPENDENT CLAIM FEE								\$0.00
TOTAL FILING FEE								\$890.00

Please charge any additional fees or credit overpayment to Deposit Account No. 13-2725. A duplicate of this sheet is enclosed.

MERCHANT & GOULD P.C.  
 P.O. Box 2903, Minneapolis, MN 55402-0903  
 (612) 332-5300

By:   
 Name: Ronald A. Daignault  
 Reg. No. 25,968  
 Initials: RADaignault/rw

\*235  
 52\*

(PTO TRANSMITTAL - NEW FILING)

S/N unknown

531 Rec'd PCT

10/018719  
14 DEC 2001  
PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:	Becker, et al.	Docket No.:	13390.2USWO
Serial No.:	unknown	Filed:	concurrent herewith
Int'l Appln No.:	PCTEP00005517	Int'l Filing Date:	June 15, 2000
Title:	USE OF GROWTH HORMONE (HGH) FOR THE TREATMENT OF SEXUAL FUNCTIONAL DISTURBANCES		

CERTIFICATE UNDER 37 CFR 1.10

'Express Mail' mailing label number: EL669945412US

Date of Deposit: December 14, 2001

I hereby certify that this paper or fee is being deposited with the United States Postal Service 'Express Mail Post Office To Addressee' service under 37 CFR 1.10 and is addressed to the Commissioner for Patents, Washington, D.C. 20231.

By: 

Name: Chris Stordahl

PRELIMINARY AMENDMENT

Box PCT  
Assistant Commissioner for Patents  
Washington, D. C. 20231

Dear Sir:

In connection with the above-identified application filed herewith, please enter the following preliminary amendment:

IN THE ABSTRACT

Insert the attached Abstract page into the application as the last page thereof.

A courtesy copy of the present specification is enclosed herewith. However, the World Intellectual Property Office (WIPO) copy should be relied upon if it is already in the U.S. Patent Office.

REMARKS

A new abstract page is supplied to conform to that appearing on the publication page of the WIPO application, but the new Abstract is typed on a separate page as required by U.S. practice.

10018719-032102


Applicants respectfully request that the preliminary amendment described herein be entered into the record prior to calculation of the filing fee and prior to examination and consideration of the above-identified application.

If a telephone conference would be helpful in resolving any issues concerning this communication, please contact Applicants' primary attorney-of record, Ronald A. Daignault (Reg. No. 25,968), at (612) 371.5381.

Respectfully submitted,

MERCHANT & GOULD P.C.  
P.O. Box 2903  
Minneapolis, Minnesota 55402-0903  
(612) 332-5300

Dated: December 14, 2001

By   
Ronald A. Daignault  
Reg. No. 25,968

RAD/rw

10018719-032102

10/018719

531 Rec'd PCT/ 14 DEC 2001

ABSTRACT  
PCT/EP00/05517

**USE OF GROWTH HORMONE (hGH) FOR THE TREATMENT OF SEXUAL  
FUNCTIONAL DISTURBANCES**

The invention relates to the use of the human growth hormone (hGH, GH) either on its own or in combination with active substances which result in GH stimulation, have an effect which is analogous to GH or which promote the release of IGF-I in the production of medicaments which are used to treat sexual functional disturbances in both sexes. The invention also relates to a method for treating the above-mentioned dysfunctions.

10018719-032102

CERTIFICATE UNDER 37 CFR 1.10

'Express Mail' mailing label number: EL669945412US

Date of Deposit: December 14, 2001

I hereby certify that this paper or fee is being deposited with the United States Postal Service 'Express Mail Post Office To Addressee' service under 37 CFR 1.10 and is addressed to the Commissioner for Patents, Washington, D.C. 20231.

By   
Name: Chris Stordahl